Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 1998

View Archived Issues

Scriptgen subscribes to Genome Therapeutics' PathoGenome database

Progenics receives milestone payment from Roche for HIV discovery program

Gene linked to inherited glaucoma

Bio-Technology General's OxSODrol study being continued with revised endpoints

Oxford Molecular Group enters research collaboration with Mitsubishi Chemical

Milestone reached in Millennium/Roche collaboration

Clinical update on Advanced Corneal Systems' Vitrase

NeoRx initiates phase I combination therapy trials in multiple myeloma patients

Dusa submits NDA for Levulan PDT of actinic keratoses

Berlex and Chiron file with FDA to treat progressive form of MS

Nihon Nohyaku claims arylpiperidines for schizophrenia, dementia

Banyu isolates new antitumor substance from Streptomyces

Novel antifungal compounds, kinase inhibitors discovered by Shionogi

Platelet aggregation inhibitors in development at Meiji Seika

Toyama describes novel cephalosporins for oral administration

Cephalon licenses Provigil and Myotrophin to Dompe

CHEESE study points to differing immune responses to two different protease inhibitors

IL-2 shown effective in patients with advanced-stage HIV disease

Herceptin licensed to Roche for most markets

Chemokine antagonist inhibits HIV-1 infectivity at nontoxic concentrations

CNI-1493 treatment associated with improvement in mouse model of MS

AIDS vaccine combination shows excellent prophylactic efficacy in clinical trial

Phase I results reported for new AIDS vaccine candidate

FDA approves first complete urine test for HIV

Specific NE inhibitor effective against primary lung tumors and metastases in mice

Chugai to begin clinical testing of anti-IL-6 receptor antibody

S-8510 enhances cognition and acetylcholine release in basal forebrain-lesioned rats

GOG will evaluate Avax Technologies' ovarian cancer vaccine in phase I/II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...